CLOTTING FACTORS - Detailed Answer (20 Marks)

RGUHS Standard | Sources: Robbins Pathology, Basic Medical Biochemistry, Harrison's, Scott-Brown's, Cummings Otolaryngology, with Recent Advances

1. INTRODUCTION

2. OVERVIEW OF HEMOSTASIS

VASCULAR INJURY
      |
      v
PRIMARY HEMOSTASIS
(Vasoconstriction + Platelet plug)
      |
      v
SECONDARY HEMOSTASIS
(Coagulation cascade -> Fibrin clot)
      |
      v
FIBRINOLYSIS
(Plasmin -> Clot dissolution)

3. CLOTTING FACTORS - COMPLETE LIST

4. THE COAGULATION CASCADE

DIAGRAM 1 - Classic Two-Pathway Model (Laboratory & In Vivo)

DIAGRAM 2 - Detailed Cascade with Phospholipid/Calcium Complexes

5. FLOWCHART OF THE COAGULATION PATHWAYS

A. EXTRINSIC PATHWAY (Tissue Factor Pathway - Major in vivo initiator)

Vascular Injury
      |
      v
Tissue Factor (Factor III) exposed
      |
      v
Factor VII binds TF --> Factor VIIa (autocatalytic activation)
      |
      +---> Factor X --> Factor Xa  (direct activation)
      |
      +---> Factor IX --> Factor IXa (cross-activation into intrinsic)

B. INTRINSIC PATHWAY (Contact Activation Pathway)

Negatively charged surface (collagen, glass)
      |
      v
Factor XII --> Factor XIIa  [+ HMWK + Prekallikrein]
      |
      v
Factor XI --> Factor XIa  [also activated by Thrombin - positive feedback]
      |
      v
Factor IX --> Factor IXa  [requires Ca²+]
      |
Factor IXa + Factor VIIIa + PL + Ca²+ = TENASE COMPLEX
      |
      v
Factor X --> Factor Xa

C. COMMON PATHWAY

Factor Xa + Factor Va + PL + Ca²+ = PROTHROMBINASE COMPLEX
      |
      v
Prothrombin (Factor II) --> Thrombin (Factor IIa)
      |
      v
Fibrinogen (Factor I) --> Fibrin monomers (soft clot)
      |
Factor XIIIa (activated by Thrombin + Ca²+)
      |
      v
Cross-linked Fibrin (HARD CLOT - stable)

6. ROLE OF THROMBIN - THE MASTER REGULATOR

DIAGRAM 3 - Thrombin's Multiple Roles

1. Cleaves fibrinogen to fibrin (structural clot)
2. Activates Factor XIII (fibrin cross-linking)
3. Activates Factors V, VIII, XI (positive feedback amplification)
4. Induces platelet aggregation via PAR receptors
5. Activates Protein C (anticoagulant - negative feedback via thrombomodulin)
6. Stimulates TxA2 and serotonin release (vasoconstriction)

7. FLOWCHART - VITAMIN K DEPENDENT FACTORS

Dietary Vitamin K (K1) / Gut bacteria (K2)
      |
      v
Vitamin K Epoxide Reductase (VKORC1)
      |
      v
Reduced Vitamin K (active form)
      |
      v
Gamma-carboxylation of glutamic acid residues
      |
      v
Factors II, VII, IX, X + Protein C + Protein S
(now able to bind Ca²+ and assemble on platelet membrane)
      |
WARFARIN blocks VKORC1 -> inhibits all above factors

8. ANTICOAGULANT MECHANISMS

FLOWCHART - Natural Anticoagulants

Activated Protein C (APC)
    + Protein S (cofactor)
          |
          v
Inactivates Factors Va and VIIIa
(Limits amplification of cascade)

Antithrombin III (AT-III)
          |
          v
Inhibits Thrombin (IIa), Factor Xa, IXa, XIa, XIIa
(Heparin potentiates AT-III 1000-fold)

Tissue Factor Pathway Inhibitor (TFPI)
          |
          v
Inhibits TF-VIIa-Xa complex
(Limits initiation of extrinsic pathway)

Thrombomodulin (endothelial receptor)
          |
          v
Binds Thrombin --> Activates Protein C
(Switches thrombin from procoagulant to anticoagulant)

9. FIBRINOLYSIS PATHWAY

Plasminogen
      |
t-PA (tissue plasminogen activator) - synthesized by endothelium
      |         [potentiated when bound to fibrin]
      v
Plasmin (active enzyme)
      |
      v
Cleaves Fibrin --> Fibrin Degradation Products (FDPs)
                --> D-dimers (clinical marker of thrombosis)
      |
Counterregulation:
alpha-2-plasmin inhibitor (inhibits free plasmin)
PAI-1 (inhibits t-PA)

10. LABORATORY TESTS OF COAGULATION

11. CLINICAL RELEVANCE IN ENT SURGERY

ENT-Specific Bleeding Disorders (Scott-Brown, Cummings, Dhingra, Hazarika, Stell & Maran)

• Primary (within 24 hours): surgical bleeding
• Secondary (day 5-10): due to slough of eschar - fibrinolytic excess
• Association with vWD (most common inherited bleeding disorder) and hemophilia

• History of easy bruising, prolonged bleeding after dental extraction
• Family history of bleeding
• Routine PT/aPTT before major ENT surgery
• Platelet count, bleeding time

12. CELL-BASED MODEL OF COAGULATION (Modern Concept)

FLOWCHART - Cell-Based Model

INITIATION PHASE (on Tissue Factor-bearing cells)
      |
TF-bearing cells (fibroblasts, smooth muscle) exposed after injury
      |
Factor VII binds TF --> VIIa
      |
VIIa-TF activates: Factor X --> Xa (small amount)
                    Factor IX --> IXa
      |
Small thrombin burst (insufficient for clot, but activates platelets)

         |
         v
AMPLIFICATION PHASE (on platelet surface)
         |
Thrombin activates:
- Platelets (release of ADP, TxA2, serotonin)
- Factor V --> Va
- Factor VIII from vWF-FVIII complex --> VIIIa
- Factor XI --> XIa

         |
         v
PROPAGATION PHASE (on activated platelet surface)
         |
IXa + VIIIa + PL + Ca²+ = Intrinsic Tenase
         |
Massive activation of Factor X --> Xa
         |
Xa + Va + PL + Ca²+ = Prothrombinase
         |
Massive Thrombin burst
         |
Fibrinogen --> STABLE FIBRIN CLOT

13. RECENT ADVANCES IN COAGULATION (2021-2026)

A. Convergent Model of Coagulation

B. Procoagulant Phospholipids on Circulating Blood Cells

C. Non-Factor Replacement Therapies in Hemophilia

• Emicizumab (Hemlibra): A bispecific antibody that bridges FIXa and FX, mimicking FVIIIa activity - used in Hemophilia A with and without inhibitors (approved FDA)
• Fitusiran: Anti-antithrombin siRNA - reduces AT-III to rebalance hemostasis
• Marstacimab: Anti-TFPI antibody - Phase 3 trial (BASIS trial, Blood 2025) showed significant reduction in annual bleeding rate in hemophilia A/B [PMID: 40608864]
• Concizumab: Anti-TFPI antibody, Phase 3 trial 2023 [PMID: 37646676]

D. Gene Therapy for Hemophilia

• Valoctocogene roxaparvovec (Roctavian): AAV5-based gene therapy for Hemophilia A approved by FDA (2023)
• Etranacogene dezaparvovec (Hemgenix): For Hemophilia B, AAV5-FIX gene therapy - longest follow-up data available
• Review: Chernyi et al., Biomolecules 2024 [PMID: 39062568]

E. DIC - Molecular Mechanisms

F. Damage-Associated Molecular Patterns (DAMPs) and Coagulation

14. MNEMONICS FOR EXAM

• Factors II, VII, IX, X = 2, 7, 9, 10 (and Protein C, S)

• Factor 12 (Hageman) --> 11 --> 9 --> 8 --> common pathway

• Factor 10 + 5 --> Thrombin (2) --> Fibrin (1)

15. SUMMARY TABLE - FACTOR DEFICIENCIES AND DISORDERS

SOURCES / REFERENCES

1. Robbins, Cotran & Kumar - Pathologic Basis of Disease (Robbins Pathology) - Chapter 4: Hemostasis and Coagulation Cascade (pp. 121-124)
2. Basic Medical Biochemistry - A Clinical Approach, 6e - Chapter 43: Blood Coagulation Cascade (Table 43.2, Fig. 43.3)
3. Harrison's Principles of Internal Medicine, 22E - Chapter 122: Overview of the Coagulation Cascade and Venous Thrombosis (pp. 2397-2405)
4. Scott-Brown's Otorhinolaryngology Head & Neck Surgery - Perioperative management and bleeding disorders
5. Cummings Otolaryngology Head and Neck Surgery - Hemostasis in ENT
6. Dhingra's Diseases of Ear, Nose and Throat - Pre-operative workup, bleeding disorders in ENT
7. Hazarika - ENT Surgery - Surgical hemostasis
8. Stell and Maran's Head & Neck Surgery - Operative bleeding management
9. Yong J & Toh CH. Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation. Blood. 2023 Dec 21. [PMID: 37890148]
10. Gong F et al. Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy. MedComm. 2025 Feb. [PMID: 39822757]
11. Chernyi N et al. Recent Advances in Gene Therapy for Hemophilia. Biomolecules. 2024 Jul. [PMID: 39062568]
12. Matino D et al. Marstacimab prophylaxis in hemophilia: BASIS trial. Blood. 2025. [PMID: 40608864]
13. Park S & Park JK. Back to basics: the coagulation pathway. Blood Res. 2024 Oct. [PMID: 39466528]

Exam Tip for RGUHS: For a 20-mark answer, structure as: Introduction (2) + Clotting factors list/table (3) + Extrinsic pathway flowchart (3) + Intrinsic pathway flowchart (3) + Common pathway + Thrombin (2) + Natural anticoagulants (2) + Lab tests table (2) + Clinical relevance in ENT/bleeding disorders (2) + Recent advances (1). Always draw Diagram 1 (classic cascade) and Diagram 2 (detailed with PL/Ca complexes) - examiners expect both.